NASDAQ:DRRX DURECT (DRRX) Stock Price, News & Analysis $0.67 +0.00 (+0.02%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About DURECT Stock (NASDAQ:DRRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DURECT alerts:Sign Up Key Stats Today's Range$0.64▼$0.7050-Day Range$0.50▼$0.7352-Week Range$0.48▼$1.74Volume16,699 shsAverage Volume43,381 shsMarket Capitalization$20.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. Read More DURECT Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreDRRX MarketRank™: DURECT scored higher than 11% of companies evaluated by MarketBeat, and ranked 2683rd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for DURECT.Read more about DURECT's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for DURECT are expected to decrease in the coming year, from ($0.50) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DURECT is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DURECT is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDURECT has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about DURECT's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.90% of the float of DURECT has been sold short.Short Interest Ratio / Days to CoverDURECT has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in DURECT has recently increased by 2.53%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDURECT does not currently pay a dividend.Dividend GrowthDURECT does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.19 Percentage of Shares Shorted2.90% of the float of DURECT has been sold short.Short Interest Ratio / Days to CoverDURECT has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in DURECT has recently increased by 2.53%, indicating that investor sentiment is decreasing. News and Social Media1.1 / 5News SentimentN/A Search Interest3 people have searched for DRRX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added DURECT to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, DURECT insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of DURECT is held by insiders.Percentage Held by InstitutionsOnly 28.03% of the stock of DURECT is held by institutions.Read more about DURECT's insider trading history. Receive DRRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter. Email Address DRRX Stock News HeadlinesDURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | prnewswire.comOppenheimer Sticks to Its Buy Rating for Durect (DRRX)March 30, 2025 | markets.businessinsider.comCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave. | Crypto Swap Profits (Ad)Here's Why We're A Bit Worried About DURECT's (NASDAQ:DRRX) Cash Burn SituationMarch 28, 2025 | finance.yahoo.comDURECT Corporation (NASDAQ:DRRX) Q4 2024 Earnings Call TranscriptMarch 28, 2025 | msn.comDURECT outlines $20M Phase 3 trial for larsucosterol in alcohol-associated hepatitisMarch 27, 2025 | msn.comDURECT Corporation (DRRX) Q4 2024 Earnings Call TranscriptMarch 26, 2025 | seekingalpha.comDURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 26, 2025 | prnewswire.comSee More Headlines DRRX Stock Analysis - Frequently Asked Questions How have DRRX shares performed this year? DURECT's stock was trading at $0.75 at the start of the year. Since then, DRRX stock has decreased by 11.1% and is now trading at $0.6667. How were DURECT's earnings last quarter? DURECT Corporation (NASDAQ:DRRX) posted its earnings results on Wednesday, March, 26th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.06 by $0.12. The specialty pharmaceutical company had revenue of $2.30 million for the quarter, compared to analyst estimates of $6.91 million. DURECT had a negative trailing twelve-month return on equity of 267.36% and a negative net margin of 91.54%. Read the conference call transcript. When did DURECT's stock split? DURECT's stock reverse split on Tuesday, December 6th 2022.The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of DURECT? Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DURECT own? Based on aggregate information from My MarketBeat watchlists, some other companies that DURECT investors own include CymaBay Therapeutics (CBAY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), GE Aerospace (GE), Catalyst Pharmaceuticals (CPRX) and Pfizer (PFE). Company Calendar Last Earnings3/26/2025Today7/03/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DRRX CIK1082038 Webwww.durect.com Phone(408) 777-1417Fax408-777-3577Employees80Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.32 million Net Margins-91.54% Pretax Margin-305.34% Return on Equity-267.36% Return on Assets-64.00% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.22 Sales & Book Value Annual Sales$2.03 million Price / Sales10.19 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book2.30Miscellaneous Outstanding Shares31,040,000Free Float30,049,000Market Cap$20.69 million OptionableOptionable Beta0.64 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:DRRX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.